Understanding how metabolic changes affect the immune response in metastatic breast cancer
Determining the Impact of Metabolic Adaptations on the Immune-Tumor Microenvironment in Metastatic Breast Cancer
['FUNDING_R01'] · ROSWELL PARK CANCER INSTITUTE CORP · NIH-11058584
This study is looking at how certain cancer cells in triple-negative breast cancer adapt to survive and avoid being attacked by the immune system, focusing on a specific enzyme called PFKFB4, to find new ways to boost treatment and help patients fight their cancer better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ROSWELL PARK CANCER INSTITUTE CORP (nih funded) |
| Locations | 1 site (BUFFALO, UNITED STATES) |
| Trial ID | NIH-11058584 on ClinicalTrials.gov |
What this research studies
This research investigates the tumor microenvironment in triple-negative breast cancer (TNBC) and how tumor cells adapt to limited nutrients and evade immune detection. It focuses on a specific enzyme, PFKFB4, which may drive aggressive cancer behavior and influence patient outcomes. By studying the effects of PFKFB4 on tumor growth and immune response, the research aims to identify new therapeutic targets that could enhance anti-tumor immunity and improve treatment responses. The approach includes advanced imaging techniques and genetic analysis to understand the relationship between metabolism and immune function in tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those with metastatic disease.
Not a fit: Patients with non-metastatic breast cancer or other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to fight metastatic breast cancer.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways to improve cancer treatment outcomes, suggesting this approach may be effective.
Where this research is happening
BUFFALO, UNITED STATES
- ROSWELL PARK CANCER INSTITUTE CORP — BUFFALO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DASGUPTA, SUBHAMOY — ROSWELL PARK CANCER INSTITUTE CORP
- Study coordinator: DASGUPTA, SUBHAMOY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: aggressive breast cancer, anti-cancer therapy